__timestamp | Celldex Therapeutics, Inc. | GSK plc |
---|---|---|
Wednesday, January 1, 2014 | 20622000 | 8246000000 |
Thursday, January 1, 2015 | 33837000 | 9232000000 |
Friday, January 1, 2016 | 35979000 | 9366000000 |
Sunday, January 1, 2017 | 25003000 | 9672000000 |
Monday, January 1, 2018 | 19269000 | 9915000000 |
Tuesday, January 1, 2019 | 15426000 | 11402000000 |
Wednesday, January 1, 2020 | 14456000 | 11456000000 |
Friday, January 1, 2021 | 20488000 | 10975000000 |
Saturday, January 1, 2022 | 27195000 | 8372000000 |
Sunday, January 1, 2023 | 30914000 | 9385000000 |
Unveiling the hidden dimensions of data
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, GSK plc and Celldex Therapeutics, Inc. have taken different paths in optimizing these costs.
From 2014 to 2023, GSK plc consistently maintained high SG&A expenses, peaking at approximately $11.5 billion in 2020. Despite this, GSK's expenses showed a slight downward trend, decreasing by about 18% by 2022. In contrast, Celldex Therapeutics, Inc. exhibited a more volatile pattern, with expenses fluctuating between $14 million and $36 million. Notably, Celldex's SG&A costs surged by 50% from 2020 to 2023, indicating a strategic shift or expansion.
While GSK's large-scale operations justify its higher expenses, Celldex's recent increase suggests a potential growth phase. Understanding these trends offers valuable insights into each company's strategic priorities.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Celldex Therapeutics, Inc.
Breaking Down SG&A Expenses: GSK plc vs Biogen Inc.
SG&A Efficiency Analysis: Comparing GSK plc and Summit Therapeutics Inc.
Cost Management Insights: SG&A Expenses for GSK plc and MorphoSys AG
Revenue Showdown: GSK plc vs Celldex Therapeutics, Inc.
Selling, General, and Administrative Costs: Takeda Pharmaceutical Company Limited vs Celldex Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Catalent, Inc. or Celldex Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Sarepta Therapeutics, Inc. and Celldex Therapeutics, Inc.
Corcept Therapeutics Incorporated vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Merus N.V. and Celldex Therapeutics, Inc.
Agios Pharmaceuticals, Inc. and Celldex Therapeutics, Inc.: SG&A Spending Patterns Compared
Celldex Therapeutics, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?